The FHI Clinical team of Scientific Advisory Experts serves as consultants to support our global programs and operations. Together, we will promote best practices, lessons learned and thought leadership as we advance local solutions and conduct rigorous research.
Our approach rests on the belief that alliances should be mutually beneficial, focus on community needs and spur innovation. Working together, we are able to deliver more sustainable and equitable solutions and amplify our impact.
Interested in contributing? Please complete a profile to be considered as a Scientific Advisory Expert.
U.S.A (Headquarters)
359 Blackwell Street, Suite 200, Durham, NC 27701 USA
South Africa
121 Amkor Road, Lyttelton Manor, Centurion, 0157, SOUTH AFRICA
Kenya
Britam Towers, 24th Floor, Hospital Road, Upper Hill KENYA
Liberia
The Cape Hotel, Mamba Point, Monrovia LIBERIA
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Anne Blanchard is a Clinical Research Executive Consultant in Latin America. Previously, she was CEO and involved in quality assurance for more than 10 years (11/2008 to 12/2019) at a regional contract research organization (CRO), leading numerous projects in Argentina, Brazil, Chile, Mexico, Bolivia and Colombia. She began her career in clinical research in 1997, when she worked for a multinational CRO in Argentina. Since then, Anne has been involved in clinical monitoring and management for both the biopharmaceutical and medical device industry and academic-based research. As part of her experience, she managed clinical trial implementation for parasitic (Chagas, hookworm, leishmaniasis) and viral (Zika, hepatitis C, HIV, RSV, and several types of influenza) diseases.
Anne is internationally ICH-certified by the Association of Clinical Research Professionals (ACRP) as a clinical research associate (CRA) since 2004 and as a clinical project manager since 2020 and was an Item Writer for the CCRA exam for 4 years. Anne was also part of the editorial group of the Barnett International “GCP Question and Answer Guide” (Section for Latin America) between 2012 and 2019. Anne has authored several articles in publications such as The Monitor and GCP Journal, presented at several international conferences and hosted webinars and in-person trainings related to the implementation of clinical research studies, regulations and oversight for compliance in Latin America. In 2015, she won the Outstanding Leadership in Clinical Research as a CRA Award by ACRP and is now completing her third term as elected member of the Board of Trustees within the organization. Anne has also participated in the writing of local clinical research regulations in Argentina and coordinated the writing of National Plans to support overall clinical research activity.
Since 2005, Anne is the President and Executive Director of Fundacion Dra. Cecilia Grierson, a regional non-for-profit organization dedicated to supporting academic and investigator-initiated research focused mainly in infectious diseases, community awareness about clinical research participation and education about the life of Cecilia Grierson, Anne’s great-aunt and the first woman to become a physician in Argentina in 1889.
Anne studied Biology at the University of Buenos Aires and completed her postgraduate in Monitoring of Clinical Trials and Clinical Research in the AMA (Argentine Medical Association) in 2001.
Robert Dickson is an Associate Professor in the Division of Pulmonary and Critical Care Medicine and the Department of Microbiology and Immunology at the University of Michigan. Clinically, he cares for patients in the Medical Intensive Care Unit, the General Pulmonary clinic, and the county tuberculosis clinic. His laboratory studies the role of lung and gut microbiota in sepsis, acute respiratory distress syndrome, and chronic lung disease. His research program specializes in integrative translational research, spanning from molecular characterization of respiratory microbiota to animal modeling of sepsis and lung injury to prospective trials of human subjects.
Dr. Dickson received his MD from the Duke University School of Medicine, then completed a residency in Internal Medicine at the University of Washington, followed by a year as Chief Medical Resident at Harborview Medical Center. He completed his fellowship in Pulmonary and Critical Care Medicine at the University of Michigan, where he has been on faculty since 2015. He serves as Senior Editor of “Microbiome,” a Specialist Editor of “European Respiratory Journal,” and a member of the Editorial Boards of the “American Journal of Respiratory and Critical Care Medicine” and “Lancet Respiratory Medicine.” His research is funded by the National Institutes of Health (NIH), the National Science Foundation (NSF), and the European Commission.
Dr. Robert W. Frenck is a Professor of Pediatrics in the Division of Infectious Diseases at Cincinnati Children’s Hospital Medical Center (CCHMC). He is Board Certified in General Pediatrics, as well as Pediatric Infectious Diseases. In addition to providing care to children with complex infectious problems, Dr Frenck is the Director of the James Gamble Center for Vaccine Research at CCHMC and the Executive Chair of the CCHMC Institutional Review Board (IRB). Dr. Frenck’s research interests are in evaluating vaccines with a particular focus on enteric diseases. Dr. Frenck is active in the American Academy of Pediatrics and is on the Executive Committee for the Section on Infectious Diseases (SOID). Dr Frenck has published over 100 articles in the peer-reviewed medical literature and presented his research at both the national and international levels.
Dr. Frenck received his undergraduate degree from the University of California at San Diego in 1977 followed by his doctor of medicine degree from the University of Texas Health Science Center at Houston in 1981. He trained at the National Naval Medical Center in Bethesda, Maryland, completing his pediatric residency in 1984. After three years as a general pediatrician at the US Naval Hospital, Japan, he entered pediatric infectious disease fellowship training at the University of Texas Health Science Center at Houston, which he completed in 1990.
Dr. Cheryl Keech works to develop solutions for vaccine-preventable diseases by leading strategic product development; designing innovative, fit-for-purpose clinical trials; working to achieve operational excellence; and developing strong global partnerships. Her goal is to provide the optimal benefit-to-risk profile for a potential vaccine throughout all stages of clinical development. Dr. Keech has led clinical development programs for multiple vaccine platforms and within multiple organizations (GlaxoSmithKline, PATH, PPD, Novavax, ILiAD Biotechnologies). She began her career as a practicing internist at Indiana University Medical Center and then joined Eli Lilly and worked in the fields of osteoporosis, women’s health, cardiovascular disease and critical care prior to focusing on vaccine development. She is a certified Six Sigma Black Belt. Dr. Keech has experience spanning all major markets, global regions, World Bank economies and phases of development (pre- and post-licensure). She has had the pleasure of partnering with multiple organizations, gaining insights into licensure pathways, national and international recommendations for use, health technology requirements, assay development needs, building strong value propositions and national tendering requirements. She has a passion to ensure vaccines can be developed and deployed to provide global health equity.
Dr. Kelly McKee is currently a Senior Scientific and Medical Advisor at Pharm-Olam and an independent consultant; he was formerly the Chief Medical Officer at Pharm-Olam. Dr. McKee has served in various roles at other organizations, including Vice President of Vaccines and Public Health at IQVIA (previously Quintiles IMS) and as research virologist and immunologist in the United States Army.
He has over 30 years of experience in research, development and public health, with expertise in vaccines, respiratory viral infections, viral hemorrhagic fevers and other “emerging” diseases and sexually transmitted infections. Dr. McKee has authored or co-authored over 100 peer-reviewed publications and textbook chapters.
He started his career as a clinical doctor in Pakistan and England. During his initial career, he was registered with the General Medical Council in the United Kingdom and worked in Essex, England with the National Health Service.
As a public health and development specialist, he is well-versed with health programs including project design, management, monitoring and evaluation; strategic information management and planning; logical framework analysis; organizational development; and research, training and facilitation for both international and local governmental and non-governmental organizations (NGOs). He has provided managerial and technical expertise in the fields of sexual and reproductive health (including all aspects of HIV/AIDS/sexually transmitted infection (STI) treatment, prevention and care); the health sector including tuberculosis for various organizations such as community-based organizations, NGOs and international NGOs.
Hasan has cutting-edge experience from two decades in the field of health programs management. Prior to joining USAID, Hasan worked as Country Director in the Pakistan country office with a US-based organization (FHI 360); Project Manager of a Global Fund for AIDS, Tuberculosis and Malaria (GFATM) funded health project; National Project Manager of a World Bank-funded project related to delivery of a package of primary health care and STI management, voluntary counseling and testing, and behavior change communication (BCC); Senior Director with Family Planning Association of Pakistan (FPAP); and full member of the International Planned Parenthood Federation (IPPF), implementing various programs related to maternal-child health (MCH), sexual and reproductive health (SRH) and family planning.
Hasan also has expertise, as a team member and leader, in overall design and implementation of qualitative and quantitative research; baseline, midterm and end evaluations; and behavioral surveillance surveys funded by the World Bank, USAID, DFID, JTF, Groupe Development (GD) and the Pakistan Medical and Research Council. His diverse research experience spans from research on commercial sexual exploitation of children to a multicenter National Study of Reproductive Tract Infections funded by the DFID.
Over the years, owing to his various assignments, he has had opportunities to be trained both locally and overseas in the fields of program monitoring and evaluation, quality assurance and improvement, delivery of quality health/clinical services, development and implementation of targeted BCC strategies and interventions, integration of BCC activities with other program activities, development of BCC materials including documentaries, development of standard operating procedures, and clinical operational guidelines (COGS) for health service delivery. Hasan has experience writing subagreements for grants funded by USAID adhering to the Mandatory Standard Provisions for Non-US and non-governmental recipients As a team leader for health-related projects, he provided guidance and strategic direction to multidisciplinary teams; has been implementing, managing and actively involved in preparation of implementation plans, annual work plans, budgets and monitoring systems; and has maintained contacts and liaised with private and public sector stakeholders and partners at provincial and national levels.
Dr. Falgunee Parekh is Founder and Principal Scientist of EpiPointe, a woman-owned small business focused on the development and implementation of clinical research studies for various infectious and emerging diseases including malaria, dengue, Zika, brucellosis, Lassa fever, influenza and tuberculosis. She has led the development of field epidemiology studies and clinical trials for vaccines and interventions targeted at infectious diseases in international settings including South America, South Asia, West and East Africa and former Soviet Union countries. Her research interests focus on assessing the epidemiology and immunologic factors associated with severe disease versus protection and how this informs the development and testing of vaccines and therapeutics against infectious diseases. She also currently serves on the leadership committee for the Global Health Security Agenda Consortium.
Dr. Stephen B. Thomas is a tenured Professor in the Department of Health Policy and Management in the School of Public Health and Director of the Maryland Center for Health Equity (MCHE) at the University of Maryland in College Park. Prior to joining the faculty in 2010, he served as the Director of the Center for Minority Health in the Graduate School of Public Health at the University of Pittsburgh from 2000-2009.
He is a highly experienced principal investigator (PI), having served as PI of multiple five-year NIH-NIMHD P60 grants titled “Excellence in Partnership through Community Outreach, Research on Health Disparities and Training (EXPORT)” (5P60 MD000207; 2002-2007) and the Research Center of Excellence in Minority Health Disparities (7 P60 MD000207, 2007-2012). With Dr. Quinn, Dr. Thomas was the joint PI of the Center of Excellence in Race, Ethnicity and Health Disparities Research (P20 MD006737, 2012-2017, NIMHD). He also served as PI (along with Dr. Quinn) on a prestigious Grand Opportunity (“GO”) grant sponsored by the Office of the Director, NIH, NIMHD, and American Recovery and Reinvestment Act (ARRA) titled “Bioethics Research Infrastructure Initiative: Building Trust between Minorities and Researchers” (7RC2MD004766).
Over the decades, he has developed a significant network of relationships and leadership roles across multiple health disparity-influencing sectors including academic researchers; healthcare providers and service organizations; community leaders; national foundations; and local, state, and federal policymakers. He has specific expertise in the development, implementation and evaluation of community-engaged minority health and health disparity interventions. He also has extensive experience in overcoming barriers associated with the legacy of the Tuskegee Syphilis Study (1932-1972) and conducting scientifically sound and culturally tailored community-based interventions designed to eliminate racial and ethnic disparities to achieve health equity. He believes in team science and building trust with minority communities by first addressing their unmet health needs. Once trust is established, opportunities to conduct research can flourish.
He serves on the Board of Directors for Doctors Community Hospital in Prince George’s County and is a founding member of the leadership team for the Totally Linking Care Coalition composed of five hospital systems. Nationally, he serves on the Institutional Review Board of the All of US research initiative, a major NIH longitudinal study seeking to enroll one million Americans. He currently serves on the Advisory Board of the Health Equity Research Initiative of the Robert Wood Johnson Foundation.
Dr. Gayani Tillekeratne is an Assistant Professor in the Division of Infectious Diseases at Duke University and an Assistant Research Professor in the Duke Global Health Institute. She serves as an attending physician at the Durham Veterans Affairs Medical Center in infectious diseases and general medicine services. She is also an adjunct professor in the Faculty of Medicine, University of Ruhuna, Sri Lanka.
Dr. Tillekeratne serves as the faculty lead for Duke’s infectious diseases program in Sri Lanka, overseeing a program that has performed surveillance for acute febrile and respiratory infections through large longitudinal cohorts over the past decade. Her research interests focus on using novel diagnostics to improve the diagnosis and management of these infections in resource-limited settings, particularly with regards to targeting antimicrobials and improving antimicrobial stewardship.
Dr. Lucas Tina works as the Deputy Director of Clinical Operations and Principal Investigator at the Kenya Medical Research Institute (KEMRI)-Centre for Clinical Research/US Army Medical Research Directorate-Africa.
He has been a clinical investigator in several successful drug and vaccine trials, including the multicenter, multicountry phase III RTS,S malaria vaccine trial in Africa, and the principal investigator for a study evaluating the safety and immunogenicity of a bivalent oral polio vaccine (bOPV) in newborn infants aimed at obtaining World Health Organization (WHO) prequalification.
Dr. Tina’s research and advocacy centers around the discovery, development and delivery of medical interventions to neglected tropical diseases, malnutrition and other emerging infectious diseases.
Roger is currently the Chief Medical Officer of Molecular Templates, a clinical-stage biotechnology company in New York developing novel immunotoxins. Prior to joining Molecular Templates, Roger was the CMO at Rgenix/Inspirna developing a novel immune-oncology compound and a metabolic inhibitor. Previously, he was CMO/CSO for Napo Pharmaceuticals and Jaguar Animal Health, developing first-in-class, FDA-approved botanicals as novel antidiarrheals. Roger spent over nine years at Novartis, most recently as Global Program Head responsible for all early and late-stage development activities of antimalarials, including Coartem and two compounds in Phase 2 development, including generating a collaboration agreement with Medicines for Malaria Venture and the Bill and Melinda Gates Foundation. Previously, Roger was responsible for global clinical development activities for several oncology compounds including the successful NDA filing of Jakavi and Tasigna and an sNDA for Glivec.
Dr. Christopher Woods is a professor in the Departments of Medicine and Pathology at Duke University, an adjunct associate professor in Epidemiology at the University of North Carolina-Chapel Hill School of Public Health, and an adjunct associate professor in the Emerging Infections Program at the Duke-National University of Singapore Graduate Medical School.
He is Executive Director of the Hubert-Yeargan Center for Global Health and Associate Director for Applied Genomics in the Duke Center for Applied Genomics & Precision Medicine (CAGPM) as well as the Global Health lead for the Duke Tropical Conservation Initiative. Clinically, he is Chief of Infectious Diseases and hospital epidemiologist for the Durham VA Medical Center.
Dr. Jon “Ben” Woods is a pediatric infectious disease physician and retired United States Air Force Colonel. Before supporting FHI, he was President of HJF Medical Research International (HJFMRI), a subsidiary non-profit of the Henry Jackson Foundation for the Advancement of Military Medicine. Prior to HJFMRI, he was Senior Antimicrobial Resistance (AMR) and Tuberculosis Technical Advisor to the Global Health Bureau at USAID. He has broad US domestic and international infectious disease clinical, programmatic and research experience spanning over two decades. His experience ranges from directing the US Army’s medical research field station in Kisumu, Kenya, overseeing pediatric malaria vaccine trials and infectious disease surveillance, serving as the Defense Intelligence Agency’s lead Medical WMD Advisor and Subject Matter Expert (SME) for design of their deployable microbial forensics laboratory, to supporting investigational new drug (IND) applications for emerging and biological warfare threat agents and running the biosafety level-4 (BSL-4) treatment facility while at the US Army Medical Research Institute for Infectious Disease (USAMRIID) at Fort Detrick, Maryland.
Dr. Woods received his Doctor of Medicine degree from the Uniformed Services University of the Health Sciences (USUHS), completed residency training in pediatrics at Wright Patterson Air Force Base Hospital/Wright State University and his fellowship in pediatric infectious diseases at the USUHS, where his research focused on animal models of enterohemorrhagic Escherichia coli disease.